Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

564.81 -5.46 (-0.96%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	831,085
Open	565.00
Bid (Size)	553.00 (200)
Ask (Size)	574.57 (40)
Prev. Close	570.27
Today's Range	551.30 - 577.86
52wk Range	266.98 - 607.89
Shares Outstanding	44,891,523
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF

March 31, 2026

In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso...

Via MarketMinute

Chips Down, Ackman Up: How Iran, the Fed, and a Viral Post Defined Monday's Market ↗

March 31, 2026

Via Chartmill

Performance

YTD	+13.7%	+13.7%
1 Month	+16.4%	+16.4%
3 Month	+15.3%	+15.3%
6 Month	+24.6%	+24.6%
1 Year	+93.1%	+93.1%

More News

Why United Therapeutics (UTHR) Stock Is Up Today

March 30, 2026

Via StockStory

Traders are paying attention to the gapping stocks in Monday's session. ↗

March 30, 2026

Via Chartmill

United Therapeutics Corp. (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗

March 28, 2026

Via Chartmill

United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗

March 04, 2026

Via Chartmill

United Therapeutics Corp. (NASDAQ:UTHR) Reports Record Annual Revenue Despite Q4 Top-Line Miss ↗

February 25, 2026

Via Chartmill

United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

March 30, 2026

From United Therapeutics Corporation

Via Business Wire

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

March 30, 2026

Via StockStory

Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers

March 23, 2026

Via StockStory

2 Mid-Cap Stocks for Long-Term Investors and 1 We Avoid

March 19, 2026

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm

March 18, 2026

Via StockStory

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗

March 16, 2026

Via The Motley Fool

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗

March 16, 2026

Via The Motley Fool

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

March 11, 2026

From United Therapeutics Corporation

Via Business Wire

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

March 09, 2026

Via StockStory

United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program

March 09, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference

March 03, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

March 02, 2026

From United Therapeutics Corporation

Via Business Wire

2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm

February 26, 2026

Via StockStory

Why United Therapeutics (UTHR) Shares Are Sliding Today

February 26, 2026

Via StockStory

The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough

February 26, 2026

Via Finterra

United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’

February 26, 2026

Via Finterra

MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗

February 25, 2026

Via Stocktwits

United Therapeutics (NASDAQ:UTHR) Misses Q4 CY2025 Revenue Estimates

February 25, 2026

Via StockStory

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?

Yes, United Therapeutics Corporation - Common Stock is publicly traded.

What exchange does United Therapeutics Corporation - Common Stock trade on?

United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for United Therapeutics Corporation - Common Stock?

The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market

What is the current price of United Therapeutics Corporation - Common Stock?

The current price of United Therapeutics Corporation - Common Stock is 564.81

When was United Therapeutics Corporation - Common Stock last traded?

The last trade of United Therapeutics Corporation - Common Stock was at 04/02/26 04:00 PM ET

What is the market capitalization of United Therapeutics Corporation - Common Stock?

The market capitalization of United Therapeutics Corporation - Common Stock is 25.36B

How many shares of United Therapeutics Corporation - Common Stock are outstanding?

United Therapeutics Corporation - Common Stock has 25B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.